Skip to content

Study on the effect of luteal long-acting long-term protocol in different ovarian response populations

Study on the effect of luteal long-acting long-term protocol in different ovarian response populations

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500105531
Enrollment
Unknown
Registered
2025-07-04
Start date
2025-07-10
Completion date
Unknown
Last updated
2025-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Interventions

Poor ovarian response luteal long-acting long-term protocol:None
Poor ovarian response antagonist protocol:None
Normal ovarian response luteal long-acting long-term protocol:None
Normal ovarian response antagonist protocol:None
High ovarian response luteal long-acting long-term protocol:None
High ovarian response antagonist protocol:None

Sponsors

Shenyang Women’s and Children’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
No minimum to 42 Years

Inclusion criteria

Inclusion criteria: 1. The ovulation induction program adopts a lluteal long-acting long-term protocol or antagonist protocol; 2. Patients undergoing IVF/ICSI-ET assisted pregnancy for the first time 3. Clinical cases and laboratory information are complete.

Exclusion criteria

Exclusion criteria: 1. Abnormal uterine morphology, such as uterine malformation: underdeveloped uterus, uterine septum, bicornuate uterus, unicornuate uterus, bicornuate uterus, residual horn uterus, etc; Intrauterine adhesions, etc; 2. History of recurrent spontaneous abortion; 3. Severe endometriosis; 4. Patients who require pre-implantation genetic diagnosis/screening due to genetic diseases, etc; 5. Severe tumors with a history of radiotherapy and chemotherapy; Patients with unilateral/bilateral hydrosalpinx who have not undergone surgical treatment or hydrosalpinx puncture; 6. Sperm supply or egg receiving cycle; 7. Age>42 years old 8. Patients with missing data.

Design outcomes

Secondary

MeasureTime frame
Synchronization of follicular development;Implantation rate;Clinical pregnancy rate;Number of retrieved oocytes;Cycle cancellation rate;Total dose of Gn used and Gn duration;Number of MII oocytes;2PN rate;Good-quality embryo rate;LH addition timing;

Primary

MeasureTime frame
Live birth rate;

Countries

China

Contacts

Public ContactYannan Zhao

Shenyang Women’s and Children’s Hospital

yannanzhao1993@163.com+86 151 4009 1931

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026